Antiphospholipid syndrome

Arthritis Research and Therapy

Volumn 10, Issue 6, 2008, Pages

  Espinosa, Gerard ^a   Cervera, Richard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY;

ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN FUNCTION; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CAPILLARITIS; CELL ACTIVATION; CLINICAL FEATURE; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEMYELINATING DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL MICROPARTICLE; HEMOSTASIS; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MICROANGIOPATHY; MULTIPLE ORGAN FAILURE; MYELITIS; NONHUMAN; PATHOGENESIS; RECURRENT ABORTION; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOSIS; TROPHOBLAST; ANIMAL; COMPLEMENT CLASSICAL PATHWAY; IMMUNOLOGY;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; THROMBOSIS;

EID: 67649111353     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2536     Document Type: Review

References (62)

1. Miyakis S Lockshin MD Atsumi T Branch DW Brey RL Cervera R Derksen RH De Groot PG Koike T Meroni PL Reber G Shoenfeld Y Tincani A Vlachoyiannopoulos PG Krilis SA International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 2006, 4:295-306. 10.1111/ j.1538-7836.2006.01753.x 16420554
2. Urbanus RT Derksen RH de Groot PG Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome Blood Rev 2008, 22:93-105. 10.1016/j.blre.2007.09.001 17964017
3. Salmon JE de Groot PG Pathogenic role of antiphospholipid antibodies Lupus 2008, 17:405-411. 10.1177/0961203308090025 18490417
4. Cervera R Piette JC Font J Khamashta MA Shoenfeld Y Camps MT Jacobsen S Lakos G Tincani A Kontopoulou-Griva I Galeazzi M Meroni PL Derksen RH de Groot PG Gromnica-Ihle E Baleva M Mosca M Bombardieri S Houssiau F Gris JC Quéré I Hachulla E Vasconcelos C Roch B Fernández-Nebro A Boffa MC Hughes GR Ingelmo M Euro-Phospholipid Project Group Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Arthritis Rheum 2002, 46:1019-1027. 10.1002/art.10187 11953980
5. Asherson RA Cervera R Unusual manifestations of the antiphospholipid syndrome Clin Rev Allergy Immunol 2003, 25:61-78. 10.1385/CRIAI:25:1:61 12794262
6. Ruiz-Irastorza G Khamashta MA The treatment of antiphospholipid syndrome: A harmonic contrast Best Pract Res Clin Rheumatol 2007, 21:1079-1092. 10.1016/j.berh.2007.10.003 18068863
7. Ruiz-Irastorza G Hunt BJ Khamashta MA A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies Arthritis Rheum 2007, 57:1487-1495. 10.1002/art.23109 18050167
8. Derksen RH Khamashta MA Branch DW Management of the obstetric antiphospholipid syndrome Arthritis Rheum 2004, 50:1028-1039. 10.1002/ art.20105 15077285
9. Galli M Borrelli G Jacobsen EM Marfisi RM Finazzi G Marchioli R Wisloff F Marziali S Morboeuf O Barbui T Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Blood 2007, 110:1178-1183. 10.1182/ blood-2007-01-066043 17440049
10. Blank M Krause I Fridkin M Keller N Kopolovic J Goldberg I Tobar A Shoenfeld Y Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome J Clin Invest 2002, 109:797-804. 150905 11901188
11. Miesbach W Asherson RA Cervera R Shoenfeld Y Gomez Puerta J Bucciarelli S Espinosa G Font J Members of CAPS Registry Group The catastrophic antiphospholipid (Asherson's) syndrome and malignancies Autoimmun Rev 2006, 6:94-97. 10.1016/j.autrev.2006.06.012 17138251
12. Uthman I Khamashta M Ethnic and geographical variation in antiphospholipid (Hughes) syndrome Ann Rheum Dis 2005, 64:1671-1676. 1755326 15919676 10.1136/ard.2005.038448
13. Yasuda S Atsumi T Matsuura E Kaihara K Yamamoto D Ichikawa K Koike T Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant Arthritis Rheum 2005, 52:212-218. 10.1002/ art.20741 15641049
14. Camilleri RS Mackie IJ Humphries SE Machin SJ Cohen H Lack of association of beta2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications Br J Haematol 2003, 120:1066-1072. 10.1046/ j.1365-2141.2003.04187.x 12648080
15. McIntyre JA Wagenknecht DR Faulk WP Redox-reactive auto-antibodies: detection and physiological relevance Autoimmun Rev 2006, 5:76-83. 10.1016/j.autrev.2005.07.009 16338215
16. de Laat B Derksen RH van Lummel M Pennings MT de Groot PG Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change Blood 2006, 107:1916-1924. 10.1182/blood-2005-05-1943 16269621
17. Lutters BC Meijers JC Derksen RH Arnout J de Groot PG Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes J Biol Chem 2001, 276:3060-3067. 10.1074/jbc.M008224200 11053420
18. Shoenfeld Y Ziporen L Lessons from experimental APS models Lupus 1998, 7(Suppl 2):158-S161. 9814695
19. Lin WS Chen PC Yang CD Cho E Hahn BH Grossman J Hwang KK Chen PP Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases Arthritis Rheum 2007, 56:1638-1647. 1950582 17469158 10.1002/art.22522
20. Ma K Simantov R Zhang JC Silverstein R Hajjar KA McCrae KR High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II J Biol Chem 2000, 275:15541-15548. 10.1074/ jbc.275.20.15541 10809787
21. Pierangeli SS Vega-Ostertag ME Raschi E Liu X Romay-Penabad Z De Micheli V Galli M Moia M Tincani A Borghi MO Nguyen-Oghalai T Meroni PL Toll-like receptor and antiphos-pholipid mediated thrombosis: In vivo studies Ann Rheum Dis 2007, 66:1327-1333. 10.1136/ard.2006.065037 17261530
22. Raschi E Testoni C Bosisio D Borghi MO Koike T Mantovani A Meroni PL Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies Blood 2003, 101:3495-3500. 10.1182/blood-2002-08-2349 12531807
23. Kornberg A Blank M Kaufman S Shoenfeld Y Induction of tissue factor-like activity in monocytes by anticardiolipin antibodies J Immunol 1994, 153:1328-1332. 8027560
24. López-Pedrera C Buendía P Cuadrado MJ Siendones E Aguirre MA Barbarroja N Montiel-Duarte C Torres A Khamashta M Velasco F Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway Arthritis Rheum 2006, 54:301-311. 10.1002/art.21549 16385547
25. Sorice M Longo A Capozzi A Garofalo T Misasi R Alessandri C Conti F Buttari B Riganò R Ortona E Valesini G Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts Arthritis Rheum 2007, 56:2687-2697. 10.1002/art.22802 17665396
26. Pennings MT Derksen RH van Lummel M Adelmeijer J Van-Hoorelbeke K Urbanus RT Lisman T de Groot PG Platelet adhesion to dimeric β-glycoprotein I under conditions of flow is mediated by at least two receptors: Glycoprotein Ibα and apolipoprotein E receptor 2' J Thromb Haemost 2007, 5:369-377. 10.1111/j.1538-7836.2007.02310.x 17096706
27. Vega-Ostertag ME Pierangeli SS Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets Curr Rheumatol Rep 2007, 9:190-197. 10.1007/s11926-007-0031-0 17531171
28. Meroni PL Gerosa M Raschi E Scurati S Grossi C Borghi MO Updating on the pathogenic mechanisms 5 of the antiphos-pholipid antibodies-associated pregnancy loss Clin Rev Allergy Immunol 2008, 34:332-337. 10.1007/ s12016-007-8055-9 18175073
29. Meroni PL Raschi E Testoni C Tincani A Balestrieri G Antiphospholipid antibodies and the endothelium Rheum Dis Clin North Am 2001, 27:587-602. 10.1016/S0889-857X(05)70222-2 11534262
30. Pierangeli SS Colden-Stanfield M Liu X Barker JH Anderson GL Harris EN Antiphospholipid antibodies from antiphospho-lipid syndrome patients activate endothelial cells in vitro and in vivo Circulation 1999, 99:1997-2002. 10209004
31. Fischetti F Durigutto P Pellis V Debeus A Macor P Bulla R Bossi F Ziller F Sblattero D Meroni P Tedesco F Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor Blood 2005, 106:2340-2346. 10.1182/blood-2005-03-1319 15956288
32. Redecha P Tilley R Tencati M Salmon JE Kirchhofer D Mackman N Girardi G Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury Blood 2007, 110:2423-2431. 1988945 17536017 10.1182/blood-2007-01-070631
33. Pierangeli SS Girardi G Vega-Ostertag M Liu X Espinola RG Salmon J Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia Arthritis Rheum 2005, 52:2120-2124. 10.1002/art.21157 15986360
34. Oku K Atsumi T Bohgaki M Amengual O Kataoka H Horita T Yasuda S Koike T Complement activation in patients with primary antiphospholipid syndrome Ann Rheum Dis 2008. PMID: 18625630. 18625630
35. Holers VM Girardi G Mo L Guthridge JM Molina H Pierangeli SS Espinola R Xiaowei LE Mao D Vialpando CG Salmon JE Complement C3 activation is required for antiphospholipid antibody-induced fetal loss J Exp Med 2002, 195:211-220. 2193604 11805148 10.1084/jem.200116116
36. Girardi G Berman J Redecha P Spruce L Thurman JM Kraus D Hollmann TJ Casali P Caroll MC Wetsel RA Lambris JD Holers VM Salmon JE Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome J Clin Invest 2003, 112:1644-1654. 281643 14660741
37. Girardi G Redecha P Salmon JE Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation Nat Med 2004, 10:1222-1226. 10.1038/nm1121 15489858
38. Staub HL Franck M Ranzolin A Norman GL Iverson GM von Muhlen CA IgA antibodies to beta2-glycoprotein I and atherosclerosis Autoimmun Rev 2006, 6:104-106. 10.1016/j.autrev.2006.06.014 17138253
39. Doria A Sherer Y Meroni PL Shoenfeld Y Inflammation and accelerated atherosclerosis: Basic mechanisms Rheum Dis Clin North Am 2005, 31:355-362. viii. 10.1016/j.rdc.2005.01.006 15922150
40. Jiménez S García-Criado MA Tàssies D Reverter JC Cervera R Gilabert MR Zambón D Ros E Bru C Font J Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome Rheumatology (Oxford) 2005, 44:756-761. 10.1093/rheumatology/keh581 15757967
41. Roman MJ Salmon JE Sobel R Lockshin MD Sammaritano L Schwartz JE Devereux RB Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus N Engl J Med 2003, 349:2399-2406. 10.1056/ NEJMoa035471 14681505
42. Distler JH Huber LC Gay S Distler O Pisetsky DS Microparticles as mediators of cellular cross-talk in inflammatory disease Autoimmunity 2006, 39:683-690. 10.1080/08916930601061538 17178565
43. Combes V Simon AC Grau GE Arnoux D Camoin L Sabatier F Mutin M Sanmarco M Sampol J Dignat-George F In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant J Clin Invest 1999, 104:93-102. 408397 10393703 10.1172/JCI4985
44. Pereira J Alfaro G Goycoolea M Quiroga T Ocqueteau M Massardo L Pérez C Sáez C Panes O Matus V Mezzano D Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state Thromb Haemost 2006, 95:94-99. 16543967
45. Cervera R Lessons from the 'Euro-Phospholipid' project Autoimmun Rev 2008, 7:174-178. 10.1016/j.autrev.2007.11.011 18190874
46. Vega-Ostertag M Harris EN Pierangeli SS Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin Arthritis Rheum 2004, 50:2911-2919. 10.1002/art.20434 15457460
47. Martinez-Cordero E Rivera Garcia BE Aguilar Leon DE Anticardiolipin antibodies in serum and cerebrospinal fluid from patients with systemic lupus erythematosus J Investig Allergol Clin Immunol 1997, 7:596-601. 9491201
48. Deane KD West SG Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: A case series and literature review Semin Arthritis Rheum 2005, 35:154-165. 10.1016/ j.semarthrit.2005.05.006 16325656
49. Salmon JE Girardi G Antiphospholipid antibodies and pregnancy loss: A disorder of inflammation J Reprod Immunol 2008, 77:51-56. 2247372 17418423 10.1016/j.jri.2007.02.007
50. Asherson RA The catastrophic antiphospholipid (Asherson's) syndrome Autoimmun Rev 2006, 6:64-67. 10.1016/j.autrev.2006.06.005 17138244
51. Erkan D Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome Autoimmun Rev 2006, 6:98-103. 10.1016/ j.autrev.2006.06.013 17138252
52. Bucciarelli S Cervera R Espinosa G Gomez-Puerta JA Ramos-Casals M Font J Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors Autoimmun Rev 2006, 6:72-75. 10.1016/ j.autrev.2006.06.007 17138246
53. Asherson RA Cervera R Microvascular and microangiopathic antiphospholipid-associated syndromes ('MAPS'): Semantic or antisemantic? Autoimmun Rev 2008, 7:164-167. 10.1016/ j.autrev.2007.11.009 18190872
54. Carmona F Font J Azulay M Creus M Fábregues F Cervera R Puerto B Balasch J Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: A multivariate analysis Am J Reprod Immunol 2001, 46:274-279. 10.1034/j.1600-0897.2001.d01-13.x 11642676
55. Giron-Gonzalez JA Garcia del Rio E Rodriguez C Rodriguez-Martorell J Serrano A Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: Prospective analysis of 404 individuals J Rheumatol 2004, 31:1560-1567. 15290736
56. Martinez-Berriotxoa A Ruiz-Irastorza G Egurbide MV Garmendia M Gabriel Erdozain J Villar I Aguirre C Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus Lupus 2007, 16:810-816. 10.1177/0961203307083316 17895304
57. Espinosa GBS Tàssies D Bové A Plaza J Reverter JC Cervera R Persistently positive antiphospholipid antibodies are related with the appearance of thrombosis during follow-up of patients with antiphospholipid syndrome [abstract] Arthritis Rheum 2007, 56:s554.
58. Criado-Garcia J Fernandez-Puebla RA Jimenez LL Velasco F Santamaria M Blanco-Molina A Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative Rev Clin Esp 2008, 208:135-137. 10.1157/13115821 18275767
59. Hughes GR Hughes syndrome (the antiphospholipid syndrome): Ten clinical lessons Autoimmun Rev 2008, 7:262-266. 10.1016/j.autrev.2007.11.017 18190889
60. Gerosa M Chighizola C Meroni PL Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases) Intern Emerg Med 2008, 3:201-203. 10.1007/s11739-008-0170-y 18592406
61. Erkan D Lockshin MD New treatments for antiphospholipid syndrome Rheum Dis Clin North Am 2006, 32:129-148. x. 10.1016/j.rdc.2005.09.004 16504826
62. Pierangeli SS Blank M Liu X Espinola R Fridkin M Ostertag MV Roye-Green K Harris EN Shoenfeld Y A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo J Autoimmun 2004, 22:217-225. 10.1016/j.jaut.2004.01.002 15041042